Navigation Links
Drug Firms Sue British Regulator Over Alzheimer's Drugs

Two drug firms and a charity for people with Alzheimer's disease began a legal challenge Monday against the downgrading of three anti-dementia drugs by British regulators.

In 2001 the National Institute for Health and Clinical Excellence (NICE), which issues guidance on how medicines should be used in Britain, recommended three drugs from US drugs giant Pfizer and Japan's Eisai.

But last year it changed its advice for patients with moderate Alzheimer's after consultation, saying instead that the drugs should only be considered as options.

The drugs -- Aricept, the brand name for donepezil; Exelon, also known as rivastigmine, and Reminyl, or galantamine -- had not proven especially effective for people with mild Alzheimer's, NICE said.

Pfizer and Eisai were due to argue in a four-day hearing at London's High Court that the effectiveness appraisal process for the drugs was unfair and that NICE's decision was both procedurally flawed and irrational.

Lawyer David Pannick, representing Eisai, told judge Linda Dobbs that the change in NICE's guidance meant that 96,600 people per year with mild Alzheimer's would not now receive the drugs.

The Alzheimer's Society, which represents people with dementia, claimed ahead of the hearing that NICE had acknowledged the drugs worked but, at a cost of 2.50 pounds per person per day (3.71 euros, 4.99 dollars), decided they were not cost effective.

"These treatments have benefitted so many families already -- where is the justice in NICE's decision to snatch them away?" Neil Hunt, chief executive of the charity, said.

Andrew Dillon, chief executive of NICE, countered that its recommendations were not unfair and were developed after three years of analysis and discussion with doctors, patients and drug makers.

"For Alzheimer's disease, drugs are only part of the care that needs to be offered," he said.

"Non-drug interventions have an important part to play and the evidence indicates that drugs are simply not effective for some patients."

Symptoms of Alzheimer's, the commonest form of dementia which affects about 450,000 people in Britain, include mood swings, confusion and withdrawal.


'"/>




Related medicine news :

1. Firms Told To Employ Those With Aspergers Syndrome
2. Drug Firms To Produce Single Pill AIDS Treatment
3. 12 Chinese Firms Appeal Against Court Ruling On Viagra
4. Drug Firms Meet Annan, Pledge on AIDS Medicines
5. Drug Firms Competing to Produce Cheap and Effective bird flu vaccine
6. US, India Firms Develop New Cure for Black Fever
7. Chemical Firms are Secretly Paying Scientists
8. Supreme Court Seeks Replies From Cola Firms
9. A Non-profit Drug Firms Injection to Fight Kala Azar Included in WHOs Model List
10. Nexus Between Psychiatrists and Drug Firms Dangerous, Say Critics
11. Milk Firms in Philippines Violate Breastfeeding Code: WHO
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/10/2016)... , ... February 10, 2016 ... ... Inc. , a full-service health care communications company offering education, research and ... resource for practitioners and specialists working in infectious diseases. , As the ...
(Date:2/10/2016)... ... February 10, 2016 , ... As part of its ongoing series of ... Each webinar features a dynamic expert and thoughtful presentation to give attendees a ... facilities. Both events are free to attend, but registration is required. ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... tracking solution, The Guard, to associations of medical professionals throughout the country. The ... including security risk assessments, policies and procedures, employee training, regulatory updates, and compliance ...
(Date:2/10/2016)... ... 10, 2016 , ... 10 Best Water is excited to announce ... brand owners that topped the list as a result of their commitment to offering ... brand was Tibet 5100, a top notch water company that specializes in providing the ...
(Date:2/10/2016)... ... 2016 , ... Ongoing news of the ravages of traumatic brain injury (TBI) ... survey that takes a closer look at cases of TBI being managed by their ... TBI among the aging population, and identifies the challenges associated with their care. , ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... A new report from business intelligence provider GBI Research ... Alzheimer,s disease market will more than double from just under $5 billion in ... Rate (CAGR) of 11%. Canada , France ... Spain , the UK, and Japan , and ... --> Canada , France , ...
(Date:2/10/2016)... Feb. 10, 2016 Urologix, the market leader ... of Benign Prostatic Hyperplasia (BPH), announces new private ownership ... , a medical device industry veteran of more than ... Liability Company.  Plymouth, Minn. ... Cooled ThermoTherapy™ and Prostiva® RF Therapy, will continue to ...
(Date:2/10/2016)... February 10, 2016 A Worldwide Clinical ... be held at Victoria Park Plaza in London ... seminar on technology and future advances for late phase research ... Lorna Graham , associate director of project management at ... up with new regulations and standards in late phase research. ...
Breaking Medicine Technology: